A pharmaceutical composition comprising a recombinant polypeptide comprising an N-terminal fragment of a listeriolysin (LLO) protein fused to a fragment of a Her-2 antigen, wherein the fragment of the Her-2 antigen consists of amino acids 303-501 or 479-655 of SEQ ID NO: 40, or amino acids 303-501 or 479-652 of SEQ ID NO: 43, or an amino acid sequence greater than 97% identical thereto, and wherein said LLO comprises a PEST sequence, or a recombinant nucleotide encoding said recombinant polypeptide, or a recombinant Listeria strain comprising a nucleotide encoding said recombinant polypeptide, for use in halting growth of established Her-2-expressing tumor cells in a subject or for use in preventing spontaneous growth of Her-2-expressing tumor cells in a subject.
